As it has been hypothesized that the low level of CD38 expressed by myeloma cells immediately after initiating treatment with daratumumab may be a reason for failure to respond to treatment attempts that have been made to increase the level of CD38 expression on myeloma cells with the hope to improve the efficiency of daratumumab (20). The gene discussed is CD38; the disease is plasma cell myeloma.